openPR Logo
Press release

Remicade Biosimilars Market 2019 | In-depth Analysis by Top Players Janssen Biotech, Inc., Merck and Company, Inc., Alvogen, Pfizer, Inc., Celltrion, Nippon Kayaku, Napp Pharmaceuticals

06-04-2019 12:59 PM CET | Health & Medicine

Press release from: Coherent Market Insights (CMI)

Remicade Biosimilars

Remicade Biosimilars

Biosimilar refers to biotherapeutic product that is similar in terms of quality, efficacy, and safety to an existing licensed reference therapeutic drug. Biological products are the fastest growing class of therapeutic products, as they offer additional treatment options and help in lowering healthcare costs. Biosimilars are almost identical copies of the originally approved drugs and can be manufactured only when the patent for the original innovator drug expires. These products are highly sensitive to smallest changes in manufacturing procedure, as these drugs possess high molecular complexity. Remicade (Infliximab) refers to a chimeric monoclonal antibody biologic licensed by U.S. FDA in 1998, as an innovative product indicated for the treatment of Crohn’s disease in adults and children. The monoclonal antibody drug was first developed in partnership by Janssen Biotech, Inc. and Merck & Co. The Remicade was later approved for its use in the treatment of ulcerative colitis, plague psoriasis, rheumatic arthritis, and spinal psoriatic arthritis in combination with methotrexate. Later, various pharmaceutical manufacturers developed biosimilars to infliximab, which lowered market share of Remicade due to cost-effective prices.

Get Free PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1769

Market Dynamics

Increasing incidence of autoimmune diseases such as plaque psoriasis and rheumatoid arthritis are expected to drive growth of the Remicade biosimilar market size. According to the American Autoimmune Related Disease Association, around 50 million American suffered from autoimmune diseases in the U.S. in 2017. Moreover, faster reaction rates of these biosimilars due to their availability in the form of intravenous mode of administration is further expected to increase the adoption of Remicade biosimilar over the forecast period. Furthermore, patent expiry of the branded versions is expected to increase the number of biosimilars for its branded counterparts thereby increasing the demand for Remicade biosimilar. However, stringent regulatory guidelines for development of these biosimilars as well as side effects of these drugs leading to risk of hospitalization are expected to restrain growth of the global Remicade biosimilar market.

Regional Insights

On the basis of region, the global Remicade biosimilar market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Europe holds a dominant position in the global Remicade biosimilar market and is expected to retain its dominance over the forecast period, owing to the presence of top market players in the region, rapid entry of biosimilars in the European market as well as high adoption rate due low price of the biosimilars. For instance, in 2018, Sandoz, a Novartis division received European Commission (EC) approval for Zessly (infliximab) a remicade biosimilar for use in Europe. The successive research and speedy approvals by the U.S. regulatory authorities for market entry of biosimilars in North America is expected to drive growth of the market over the forecast period. For instance, in December 2017, Pfizer, Inc. received the U.S. FDA approval for second biosimilar, Ifixi to Janssen’s blockbuster drug Remicade to treat rheumatoid arthritis.

Competitive Landscape

Key players operating in the global remicade biosimilar market include Janssen Biotech, Inc., Merck and Company, Inc., Alvogen, Pfizer, Inc., Celltrion, Nippon Kayaku, Napp Pharmaceuticals, and others. Market players are focused on introducing maximum number of biosimilar for multiple indications to retain their position in the global market. For instance, in July 2017, Merck & Company, Inc. in collaboration with Samsung Bioepis introduced Renflexis (infliximab-abda), a biosimilar to Remicade for the treatment of moderate to severe Crohn’s disease, active ulcerative colitis, rheumatoid arthritis, and other few disease indications.

Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/1769

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Remicade Biosimilars Market 2019 | In-depth Analysis by Top Players Janssen Biotech, Inc., Merck and Company, Inc., Alvogen, Pfizer, Inc., Celltrion, Nippon Kayaku, Napp Pharmaceuticals here

News-ID: 1763941 • Views: 556

More Releases from Coherent Market Insights (CMI)

Gems and Jewelry Market Covering Competitive Scenario & Market Dynamics througho …
Gems and jewelry consists of various jewelries that are made out of gold, platinum, gemstones, and others. Gems and jewelry is one of the fastest growing markets, as it holds customary values in several cultures across the globe. Several leading companies are aiming on investing in the marketing, advertising, and launching of new showrooms for increasing publicity and expanding their presence in the market. Get Sample Copy of This Premium
Security Paper Market : Global Industry Analysis, Trends, Market Size and Foreca …
Security paper is a paper which constitutes features that help qualify and identify a document as authentic or original. The use of security paper exemplifies the importance of a document and helps in distinguishing between authentic and counterfeit documents. It is widely used for printing currency, legal, and government documents. Get Sample Copy of This Premium Research (including full TOC, Tables and Figures)@ https://www.coherentmarketinsights.com/insight/request-sample/561 Counterfeiting of documents and currency has
Potato Processing Market Expected to Reach At a Highest Growth During Forecast P …
Potato is a starchy root vegetable, which is mainly obtained from the plant Solanum tuberosum. Potato tuber is widely processed to get a variety of food products such as chips, fries, flakes, and other convenience food. Potato is also processed for its application as filler, binder, and adhesive by various end-use industries such as paper, textile, and pharmaceuticals. Furthermore, processed potato is used in animal feed and biofuels as well.
Gelatin Market 2020 Size, Share, Development Status, Type and Application, Segme …
Gelatin is a soft protein comes from collagen obtained by boiling skin, tendons, ligaments, bones when dissolved with water. It is usually found in animal parts enriched with amino acids (as cows, pigs, and fish). This type of collagen gelatin usually helps to swallow capsules easily. According to varying sources of raw material and processing techniques, gelatin has its additional nutritional value. Gelatin is used for preparation of foods, cosmetics,

All 5 Releases


More Releases for Remicade

Remicade Biosimilar Market to Witness Exponential Growth by 2026
About the drug and drug class: Biosimilar can be defined as a type of biological product that is highly similar to an already FDA approved drug, known as reference biological product. Biosimilars are drugs licensed by U.S. FDA and European Medicine Agency (EMA) and reflect no clinical and meaningful differences from the reference products in terms of safety, purity, efficacy and effectiveness. These biosimilar drugs can only be approved for the
Remicade Biosimilar Market Growth, Forecast and Value Chain 2016 - 2026
About the drug and drug class: Biosimilar can be defined as a type of biological product that is highly similar to an already FDA approved drug, known as reference biological product. Biosimilars are drugs licensed by U.S. FDA and European Medicine Agency (EMA) and reflect no clinical and meaningful differences from the reference products in terms of safety, purity, efficacy and effectiveness. These biosimilar drugs can only be approved for the
Remicade Biosimilar Market size and forecast, 2016-2026
About the drug and drug class: Biosimilar can be defined as a type of biological product that is highly similar to an already FDA approved drug, known as reference biological product. Biosimilars are drugs licensed by U.S. FDA and European Medicine Agency (EMA) and reflect no clinical and meaningful differences from the reference products in terms of safety, purity, efficacy and effectiveness. These biosimilar drugs can only be approved for the
New Study Offers Detailed Insights on Remicade Biosimilar Market
About the drug and drug class: Biosimilar can be defined as a type of biological product that is highly similar to an already FDA approved drug, known as reference biological product. Biosimilars are drugs licensed by U.S. FDA and European Medicine Agency (EMA) and reflect no clinical and meaningful differences from the reference products in terms of safety, purity, efficacy and effectiveness. These biosimilar drugs can only be approved for the
Remicade Biosimilar Market : Opportunities and Forecast Assessment, 2016 - 2026
About the drug and drug class: Biosimilar can be defined as a type of biological product that is highly similar to an already FDA approved drug, known as reference biological product. Biosimilars are drugs licensed by U.S. FDA and European Medicine Agency (EMA) and reflect no clinical and meaningful differences from the reference products in terms of safety, purity, efficacy and effectiveness. These biosimilar drugs can only be approved for the
Remicade (Infliximab) Biosimilar Clinical Trial Insight
“Remicade (Infliximab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 17 biosimilar version of Remicade drug in clinical pipeline. Currently there are 2 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Remicade are commercially available in India, Brazil and European countries for the treatment of Ankylosing spondylitis, Crohn's disease and Rheumatoid Arthritis. The